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For successful penetration of HIV-1, the formation of a fusion pore may be required in order to accumulate critical numbers of fusion-activated
gp41 with the help of fluidization of the plasma membrane and viral envelope. An increase in temperature to 40 °C after viral adsorption at 25 °C
enhanced the infectivity by 1.4-fold. The enhanced infectivity was inhibited by an anti-CXCR4 peptide, T140, and anti-V3 monoclonal antibodies
(0.5β and 694/98-D) by post-attachment neutralization, but not by non-neutralizing antibodies (670-30D and 246-D) specific for the C5 of gp120
and cluster I of gp41, respectively. Anti-HLA-II and an anti-HTLV-I gp46 antibody, LAT27, neutralized the molecule-carrying HIV-1C-2(MT-2). The
anti-V3 antibodies suppressed the fluidity of the HIV-1C-2 envelope, whereas the non-neutralizing antibodies did not. The anti-HLA-II antibody
decreased the envelope fluidity of HIV-1C-2(MT-2), but not that of HIV-1C-2. Therefore, fluidity suppression by these antibodies represents an
important neutralization mechanism, in addition to inhibition of viral attachment.
© 2007 Elsevier Inc. All rights reserved.Keywords: HIV-1; Neutralizing antibody; Membrane/envelope fluidity; Fusion poreIntroduction
Viral neutralization consists of a decrease in the infectious
titer of a viral preparation following its exposure to antibodies.
The loss of infectivity is brought about by interference of the
antibodies bound to the viruses during any step from viral
attachment to the cells to release of the viral genome into the host
cells. The potent and broad capacity of the available neutralizing
antibodies against human immunodeficiency virus type 1 (HIV-
1) has been attributed to inhibition of fusion and/or virus
attachment to the cell surface (Klasse and Sattentau, 2002; Zwart
et al., 1991). Thus, the neutralization effects are currently well
explained by antibody coating of the virions (high-occupancy
theory of neutralization) (Klasse and Sattentau, 2002). However,
the high-occupancy theory cannot solely account for the post-
attachment neutralization (PAN) (Armstrong et al., 1996;
Edwards and Dimmock, 2001), synergistic (Zwick et al.,⁎ Corresponding author. Fax: +81 96 373 5132.
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doi:10.1016/j.virol.2007.08.0212001) and additive (Verrier et al., 2001) effects of neutralizing
antibodies, and HIV-1 neutralization by one or a few antibody
molecules (Harada, 2002). Therefore, there must be additional
mechanisms involved in HIV-1 neutralization.
Recently, we reported that small changes in the fluidity of
the plasma membrane and/or viral envelope would be in-
dispensable for modifying HIV-1 infectivity (Harada et al.,
2005). We hypothesized that fluidity-mediated accumulation of
fusion-activated domains was required to form a wide fusion
pore large enough for an enveloped viral core to pass through.
In fact, the increased or decreased fluidity changes observed
after different treatments with the same fluidity modulator, such
as glycyrrhizin (Harada, 2005) or fattiviracin FV-8 (Harada et
al., 2007), were parallel with the high or low susceptibility of
the treated cells to HIV-1 infection and fusion. These
modulators are broad antiviral agents, which are especially
effective against enveloped viruses. Furthermore, they were
found to reduce the infectivity of virions when the viruses were
pretreated (Harada, 2005; Harada et al., 2007). Notably, this
latter finding reminded us of the actions of neutralizing anti-
bodies against viral particles.
Fig. 1. Conventional neutralization of NL43-luc pseudoviruses by 694/98-D
(circles), 670-30D (squares), and 246-D (triangles)mAbs (A), and effects of 1μM
T140andHIV-1-specificmAbs (0.5β, 694/98-D, 670-30D, and 246-D) onPAEat
40 °C for 1 h after viral adsorption at 25 °C (B). All experiments in panels A andB
were carried out in triplicate, and solid lines and bars show the mean±SD.
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membrane/envelope fluidity in HIV-1 infection and neutraliza-
tion, we designed a series of experiments to examine the effects
of neutralizing antibodies on the fluidization of the HIV-1
envelope and plasma membrane. We found that these
antibodies suppressed the fluidization of the highly ordered
lipid bilayer of the viral envelope when they exerted neutra-
lization against the respective virus. These studies provide
novel insights into the cell biology of retroviral penetration and
demonstrate distinct roles for membrane fluidity at early stages
of HIV-1 penetration.
Results
Neutralization and PAN by the anti-V3, anti-C5 and anti-gp41
monoclonal antibodies
Conventional neutralization experiments were conducted by
pre-incubating viruses with the antibodies prior to their addition
to cell culture. At 1 μg/ml, the 0.5β (anti-V3) monoclonal
antibody (mAb) neutralized more than 90% of plaque-cloned
HIV-1C-2 (C-2 viruses) (Masuda et al., 1990) and X4 envelope-
pseudotyped viruses with a luciferase reporter gene (NL43-luc
viruses) (Harada et al., 2004b). Next, the neutralization
activities of human mAbs against gp120 V3 (694/98-D),
gp120 C5 (670-30D) and gp41 cluster I (246-D) were
examined. All of these mAbs were previously reported to
bind to intact clade B (IIIB) virions (Nyambi et al., 2000). As
shown in Fig. 1A, 1 μg/ml 694/98-D neutralized more than 90%
of NL43-luc viruses, similar to 0.5β, whereas 670-30D and
246-D mAbs rather enhanced the infectivity by around 1.3-fold
at all concentrations examined. Thus, 0.5β and 694/98-D mAbs
are neutralizing antibodies, whereas 670-30D and 246-D are
non-neutralizing antibodies.
NL43-luc viruses were incubated with GHOST/CXCR4
cells at 25 °C for 1 h. After this viral adsorption, the post-
adsorption steps were carried out at either 37 °C or 40 °C in the
presence or absence of the anti-CXCR4 peptide T140 or mAbs
(Fig. 1B). T140 inhibited 95% of the infection when GHOST/
CXCR4 cells were treated with 1 μM T140 before infection
with NL43-luc pseudoviruses (Harada et al., 2005). Increasing
the temperature to 40 °C during the post-adsorption steps
augmented the level of infection by 1.4-fold (Fig. 1B). This
phenomenon is hereafter referred to as post-attachment
enhancement (PAE). The PAEs were repeatedly observed by
1.5- to 2.0-fold (Harada et al., 2004a, 2005). The PAEs from
25 °C to 40 °C were strongly abrogated by 1 μM T140 (Fig.
1B), indicating that T140 could restrain the viruses from
forming multiple-site binding or accumulating fusion-activated
gp41 domains by occupying CXCR4. The PAE of 1.4-fold
observed at 40 °C was also significantly inhibited by 1 μg/ml
0.5β or 4 μg/ml 694/98-D mAbs (Fig. 1B), suggesting that
these anti-V3 mAbs could mediate PAN when the viruses were
loosely bound to the cells at 25 °C. An increased amount
(10 μg/ml) of 0.5β mAb showed the same inhibitory effect
(about 30%) on the PAE as 1 μg/ml, indicating that the PAE
inhibition by this antibody could not be solely explained bycovering the V3 loop of gp120 with antibody molecules, as was
the case for T140 occupation of CXCR4. Anti-C5 (670-30D)
and anti-gp41 (246-D) mAbs had little effects on the PAN, but
tended to enhance the PAE (Fig. 1B).
Suppression of viral envelope fluidization by neutralizing
anti-V3 antibodies
The structural and dynamic modification of envelope lipids
was examined using a spin-label method (Figs. 2 and 3). As a
negative control for C-2, 0.5β-escaped C-2 (esc.C-2) viruses
were used. More than 90% of the C-2 viruses were neutralized
by 1 μg/ml 0.5β, whereas the esc.C-2 viruses were not
affected (Masuda et al., 1990). The esc.C-2 viruses have one
point mutation in the crown of the V3-loop, resulting in
exchange of GPG to GQG. The order parameters of 0.5β-
treated C-2 viruses were higher at 25 °C, 37 °C and 40 °C
than those of control IgG (MOPC21)-treated viruses (Figs. 2A
and B; Fig. 3A), indicating that 1 μg/ml 0.5β mAb suppressed
the fluidity of the viral envelope. At 37 °C, 0.5β mAb
suppressed the fluidity by 7%. However, no such effect of
0.5β was observed in the case of the esc.C-2 viruses (Fig. 3B).
Thus, the fluidity suppression by this antibody is consistent
Fig. 3. Effects of 1 μg/ml MOPC21 (diamonds) and 1 μg/ml 0.5β (circles) on the
envelope fluidity of C-2 (A) and esc.C-2 (B) viruses. Viruses (50 ml) were
treated with each antibody at 37 °C for 40 min prior to labeling with 5-DSA for
20 min. All measurements were carried out in triplicate and the solid lines show
the mean±SD. (C) Effects of 1 μg/ml 694/98-D (n=8), 0.5 μg/ml 670-30D
(n=2), and 1 μg/ml 246-D (n=5) on the envelope fluidity of C-2 viruses. As a
control, PBS was used instead of an mAb (n=3). Bars show the mean±SD.
Fig. 2. ESR spectra of viral envelopes from intact C-2 (A), 0.5β-treated C-2 (B),
C-2(MT-2) (C), and anti-HLA-II-treated C-2(MT-2) (D) viruses at 37 °C.
Viruses (50 ml) were incubated in the presence or absence of 0.5β or anti-HLA-
II antibodies at a final concentration of 1 μg/ml at 37 °C for 40 min, and then
labeled with 5-DSA for 20 min. Virus pellets were examined by ESR
spectroscopy. The outer and inner hyperfine splittings, 2A// and 2A⊥, were
measured as indicated by the arrowheads. Asterisks indicate the spectra of free
5-DSA. The order parameters (S-values) of (A), (B), (C) and (D) are 0.736,
0.787, 0.678, and 0.772, respectively. The scale (10G) of the horizontal axis is
shown.
144 S. Harada et al. / Virology 370 (2008) 142–150with its neutralization data. Another anti-V3 mAb, 694/98-D
(1 μg/ml) also suppressed the fluidity of the C-2 envelope
(Fig. 3C). However, the non-neutralizing 670-30D (0.5 μg/ml)
and 246-D (1 μg/ml) mAbs had no effects on the fluidization
of the viral envelope (Fig. 3C). Similar effects on the plasma
membrane fluidity were obtained when MOLT-4/C-2 cells
were treated with 0.5β, 694/98-D, 670-30D and 246-D mAbs
(data not shown). Thus, the 0.5β and 694/98-D mAbs
suppressed the fluidity not only of the viral envelope but
also of the plasma membrane.
HIV-1 neutralization by antibodies against non-HIV molecules
Adsorption-blocking, namely, the high-occupancy theory,
cannot be completely excluded for the observed inhibition by
the 0.5β and 694/98-D mAbs in the neutralization experiments.
Therefore, we examined neutralization by non-HIV antibodies.FACS analyses revealed that MOLT-4 cells did not express
HLA-II molecules (Fig. 4A), whereas human T-cell leukemia
virus type I (HTLV-I)-transformed MT-2 cells carried many of
these molecules on their surface (Fig. 4B). MT-2 cells were also
positive for HTLV-I gp46 detected by neutralizing LAT27 and
non-neutralizing LAT12 antibodies (Fig. 4C). The binding
affinity of LAT27 appeared to be stronger than that of LAT12
(Fig. 4C). HIV-1C-2(MT-2) viruses that budded from HIV-1C-2-
infected MT-2 cells were expected to have both HLA-II
molecules and HTLV-I gp46 as phenotype-mixing progeny
viruses. It has been reported that HIV-1 carries more HLA-II
molecules than gp120 (Trubey et al., 2003). The anti-HLA-II
Fig. 4. Flow cytometric analysis of HLA-II expression in MOLT-4 (A) and MT-2 (B) cells, and HTLV-I gp46 expression in MT-2 cells (C). Neutralization of C-2(MT-
2) (circles) and C-2(MOLT-4) (diamonds) viruses by anti-HLA-II (D) and neutralization of C-2(MT-2) viruses by LAT27 (circles) and LAT12 (diamonds) (E) are
shown. The solid lines in panels D and E show the mean±SD of 6 independent experiments.
Fig. 5. Effects of MOPC21 (20 μg/ml), anti-HLA-II (2 μg/ml), LAT12
(20 μg/ml), LAT27 (20 μg/ml), and 0.5β (2 μg/ml) on C-2(MOLT-4) or
C-2(MT-2) virus adsorption on MOLT-4 cells. All experiments were carried out
in triplicate, and the bars show the mean±SD.
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whereas the C-2 viruses were not affected (Fig. 4D). C-2(MT-2)
viruses were also neutralized by the neutralizing LAT27
antibody, but not by the non-neutralizing LAT12 antibody
(Fig. 4E). However, 20–40 μg/ml of the LAT27 antibody only
neutralized 35% of the C-2(MT-2) viruses. In addition, the level
of neutralization quickly reached a plateau with more than
20 μg/ml of the antibody. Infection of C-2(MT-2) viruses in
MAGI cells was almost completely blocked by 0.5β or T140,
indicating that C-2(MT-2) viruses used HIV-1 gp120 and
CXCR4 for the infection (data not shown). Nevertheless, HLA-
II and HTLV-I gp46 on HIV-1 particles could be used as target
molecules for neutralization of the virus by the respective
antibodies.
One of the mechanisms proposed for HIV-1 neutralization
by antibodies against non-HIV-1 molecules is the “coating
theory,” which suggests that a dense coat of antibodies over the
virion surface could interfere with viral adsorption to cells by
steric hindrance. However, treatment of C-2(MOLT-4) or C-2
(MT-2) viruses with the anti-HLA-II, LAT12 and LAT27
antibodies did not significantly inhibit the viral attachment to
MOLT-4 cells (Fig. 5). As a positive control, 2 μg/ml of the
anti-V3 0.5β antibody suppressed C-2(MOLT-4) viral adsorp-
tion to the cells by only 50%, which could be partly explained
by 0.5β mAb-mediated blocking of gp120 V3 binding to
CXCR4. Other mechanisms, such as fluidity alterations in the
viral envelope rather than steric hindrance, may be responsible
for the HIV-1 neutralization by antibodies against non-HIV
molecules.Suppression of fluidization by neutralizing antibodies against
non-HIV molecules
At 1 μg/ml, the anti-HLA-II antibody strongly suppressed
the envelope fluidity of C-2(MT-2) viruses (Figs. 2C and D; Fig.
6A), but did not suppress that of C-2 viruses (Fig. 6B). These
findings were well correlated with the neutralization data (Fig.
4D). The anti-HLA-II suppressed the fluidity by 15% at 37 °C.
Since the anti-HLA-II antibody (2 μg/ml) was previously
reported to suppress the membrane fluidity of MT-2 cells
Fig. 6. Effects of 1 μg/mlMOPC21 (diamonds) and 1 μg/ml anti-HLA-II (circles) on envelope fluidity of C-2(MT-2) (A) and C-2 (B) viruses, and the effects of 10 μg/ml
LAT12 (squares) and 10μg/ml LAT27 (circles) on the fluidity of the viral envelope of C-2(MT-2) viruses (C) and plasmamembrane ofMT-2 cells (D). All measurements
were carried out in triplicate and the solid lines show the mean±SD.
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lower the fluidity of lipid bilayers when it binds to membranes.
The LAT antibodies at 10 μg/ml showed no significant
suppression of fluidity in the C-2(MT-2) viruses (Fig. 6C).
However, when MT-2 cells were treated with 10 μg/ml of the
LAT antibodies, the neutralizing LAT27 antibody suppressed
the plasma membrane fluidity at all temperatures examined
(Fig. 6D). In contrast, the non-neutralizing LAT12 antibody did
not show any suppressive effects on MT-2 plasma membrane
fluidity (Fig. 6D).
Discussion
The V3 loop of HIV-1 gp120 plays a critical role in
determining the cell tropism of the virus (Clapham and
McKnight, 2002). The loop is composed of approximately 35
amino acid residues with a global positive charge. An increase
in the positive charge of the loop is thought to be associated
with coreceptor usage (Hoffman and Doms, 1999; Moulard et
al., 2000; Platt et al., 2001). A single amino acid change in V3 is
able to switch viral coreceptor usage (CXCR4 or CCR5) (Hu et
al., 2000; Shimizu et al., 1999). Furthermore, the V3 domain is
considered to be the primary determinant of coreceptor usage
(Cormier and Dragic, 2002) together with V1/V2 contributions
(Dragic, 2001; Foda et al., 2001; Maeda et al., 2000). Anti-V3
antibodies strongly neutralize T-cell line-adapted strains of HIV-
1 (Gorny et al., 2002; Zhang et al., 2002), and block the fusioninduced by HIV-1 infection (Masuda et al., 1990) or gp120-
expressing cells. The antibodies may neutralize viruses by
interfering with several steps in the early phase of infection. It
has been reported that anti-V3 mAbs interfere with the ability of
gp120 and CD4 complexes to bind to CCR5 (Cormier et al.,
2001). Thus, they act as receptor-blockers. However, HIV-1
neutralization by one or a few molecules of V3-targeted mAbs
(Harada, 2002) and PAN (Armstrong et al., 1996) have been
reported, suggesting the possibility of neutralizing effects after
viral adsorption.
Engagement of the gp120 trimer with coreceptors induces
gp41 rearrangement and exposure of the hydrophobic amino
acid fusion domain, leading to fusion. The triggered fusion-
activated gp41 structures are rod-like with a bundle of six α-
helices (Clapham and McKnight, 2002). It is conceivable that
HIV-1 penetration into a cell requires a fusion-pore that is wide
enough for the viral core to pass through. Accumulation of
substantial numbers of fusion-activated gp41 structures with the
help of fluidity of the lipid bilayer membrane must be necessary
for this purpose. The formation of ring-like assemblies of fusion
proteins has been reported in studies of rabies virus (Roche and
Gaudin, 2002), baculovirus (Plonsky and Zimmerberg, 1996),
influenza virus (Markovic et al., 2001) and Semliki Forest virus
(Gibbons et al., 2003). Cell–cell fusion is temperature-
dependent (Frey et al., 1995), and a time lag of 10–20 min
between the six-helix bundle formation and fusion has been
reported after transfer from 31.5 °C to 37 °C (Golding et al.,
147S. Harada et al. / Virology 370 (2008) 142–1502002). This indicates that the formation of a fusion pore requires
a critical number of six-helix bundles.
The anti-HIV peptide T140 strongly inhibits X4 HIV-1
infection (Tamamura et al., 1998) through its specific binding to
CXCR4, as shown by the finding that 1 μM T140 could occupy
most of the CXCR4 molecules on the cell surface. As a result,
the binding of T140 to CXCR4 could prevent a loosely attached
virus from forming additional multiple-site binding. In fact, the
enhancement observed as PAE due to temperature shifts (25 °C
to 37 °C and 25 °C to 40 °C) in the present study was strongly
inhibited by T140, indicating that multiple-site binding was
functioning and blocked by T140 occupation of CXCR4
molecules. We previously reported that PAE at 40 °C requires
a time lag of 20–30 min before becoming apparent for blocking
the enhancement by T140 after transfer from 25 °C to 40 °C
(Harada et al., 2004a). This finding suggests that PAE requires
the accumulation of gp120/receptor complexes through mem-
brane fluidity, similar to the case for cell–cell fusion (Golding
et al., 2002).
In the present study, V3-targeted 0.5β and 694/98-D mAbs
inhibited the PAE of HIV-1 infection at 40 °C by 30–40% when
the cells were pre-incubated with viruses at 25 °C. The PAN by
anti-V3 antibodies was also observed when the shift was to
37 °C, but the infection was inhibited only by 10–20%. Thus,
the antibodies mediate less potent PAN at 37 °C than at 40 °C,
probably because the antibodies mainly suppress increased
infectivity (PAE) due to increased temperature. Direct occlusion
by the anti-V3 antibodies of open sites involved in the process
of multiple-site binding to cells could be a way to prevent PAE
at 40 °C. It is unknown whether these antibodies induce the
detachment of adsorbed virions from cells. However, we found
that PAE was only inhibited by 30–40% and a 10-fold higher
dose (10 μg/ml) of 0.5β showed no further inhibitory effect on
the PAE, indicating that occupancy is not likely to happen in
this case. Alternatively, the binding of the antibody to the viral
surface could affect steric alterations to the viral envelope and
restrain the envelope from enhancing the fluidity at 40 °C. In
fact, we observed that binding of 0.5β and 694/98-D to C-2
viruses induced a more ordered or rigid envelope at 37 °C.
Neutralization of simian immunodeficiency virus (SIV) by
anti-HLA and anti-hemagglutinin antibodies has previously
been reported (Vzorov and Compans, 2000). In the present
study, we also found that phenotype-mixed C-2(MT-2) viruses
were neutralized by anti-HLA-II and LAT27 antibodies,
although LAT27 exhibited a very weak neutralization activity.
The reason why LAT27 is a neutralizing antibody, but LAT12 is
not, remains unknown, although the binding affinity of LAT27
to MT-2 cells appeared to be stronger than that of LAT12. Two
possible mechanisms are proposed for the neutralization of C-2
(MT-2) viruses by antibodies against non-HIV molecules. The
first is the coating theory, which suggests that a dense coat of
antibodies over the virion surface will interfere with viral
adsorption to the cells, whereas the second is the steric alteration
theory, which suggests that structural changes caused by
binding of the antibodies will prevent penetration or uncoating
of the virus. If the first mechanism is the case, adsorption of C-2
(MT-2) viruses, but not C-2(MOLT-4) viruses, should beblocked by antibodies against non-HIV molecules. However,
we found that treatment of C-2(MOLT-4) and C-2(MT-2)
viruses with anti-HLA-II, LAT12 and LAT27 antibodies did not
significantly inhibit the viral adsorption. Instead, the anti-HLA-
II antibody suppressed the envelope fluidity of C-2(MT-2)
viruses, but not that of C-2 viruses. However, the neutralizing
LAT27 antibody showed no suppressive effect on the fluidity of
the C-2(MT-2) envelope, but did suppress the MT-2 plasma
membrane fluidity, probably due to the increased HTLV-I gp46
expression on the MT-2 plasma membrane. Currently, the
reason why the LAT27 neutralized C-2(MT-2) viruses is
unknown. More sensitive techniques to measure minute
changes of envelope fluidity might be required to explore the
mechanism.
In the present study, the levels of neutralization (more than
90%) by 1 μg/ml 0.5β and 694/98-D in conventional assays
were much stronger than that of PAN (30–40% inhibition of
PAE). PAN could be mainly exerted by suppression of the viral
envelope fluidity. Apparently, anti-V3 antibodies have multi-
farious neutralization mechanisms, such as occupancy of V3
and stabilization of envelope fluidity. We found that the anti-
HLA-II antibody showed 35% neutralization against C-2(MT-2)
viruses at the concentration of 1 μg/ml. This modest
neutralization was only achieved by suppressing the fluidity.
However, the significance or biological meaning of HIV-1
neutralization by anti-HLA-II antibodies or autoantibodies is
the extraordinary protection revealed in studies on SIV-infected
macaques vaccinated with cells expressing the same HLA
molecules as those employed to culture the SIV used for the
challenge (Arthur et al., 1995; Chan et al., 1992). Furthermore,
antibodies against HLA are frequently present in HIV-exposed
but uninfected individuals (Brown et al., 1997).
Suppressing the fluidity of the viral envelope could be one of
the essential, but additional, mechanisms for virus neutraliza-
tion because fluidity is indispensable for infectivity due to the
required formation of multiple-site binding and a fusion pore
(Harada, 2005; Harada et al., 2005, 2007). Antibodies may need
substantial amounts of epitope molecules with high binding
affinities on the plasma membrane or viral envelope to decrease
its fluidity. The mechanism for fluidity suppression by
antibodies is still unknown, but it is unlikely to be actin-
dependent as the fluidity of the viral envelope was affected. The
attachment of an antibody molecule, especially if it bridges
adjacent subunits, is assumed to cause local structural
alterations or topological changes of the integral protein,
which spreads to the whole envelope or membrane, thereby
stabilizing the fluidization for unknown reasons. Similarly,
retrocyclin 2 was reported to immobilize surface proteins by
cross-linking membrane glycoproteins (Leikina et al., 2005).
Therefore, retrocyclin 2 exhibits inhibitory effects on viral
fusion and entry. If the binding of the antibody itself is essential
for lowering the fluidity, this cannot explain the presence of
sensitizing (non-neutralizing) antibodies against viruses. Hence,
a hypothesis has been proposed that viruses bear heterogeneous
envelope molecules (Harada et al., 2004b), such as functional
and nonfunctional gp120, and non-neutralizing antibodies only
react with the nonfunctional gp120 (Poignard et al., 2003).
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switch fluidization on or off after binding of the respective
antibody. Further studies will be needed to clarify the
mechanisms involved in modifying the fluidity of lipid bilayer
membranes.
Materials and methods
Cells and culture
MOLT-4, MOLT-4/HIV-1C-2, MOLT-4/HIV-1esc.C-2 (Masuda
et al., 1990) and MT-2 (Harada et al., 1985) cells were cultured
in RPMI1640 medium (Gibco BRL, Grand Island, NY) sup-
plemented with 10% heat-inactivated fetal bovine serum (FBS),
2 mM L-glutamine, 100 IU/ml of penicillin and 0.1 mg/ml
streptomycin (complete medium). Multinuclear activation of a
galactosidase indicator (MAGI) cells derived from HeLa-CD4/
long terminal repeat-β-galactosidase cells (Kimpton and
Emerman, 1992) were maintained in complete medium
supplemented with 0.1 mg/ml G418 and 0.05 mg/ml hygro-
mycin B. GHOST/CXCR4 cells derived from a human
osteosarcoma cell line (HOS) were cultured in complete
medium supplemented with 0.2 mg/ml G418, 0.05 mg/ml
hygromycin B and 2 mg/ml puromycin as previously described
(Cecilia et al., 1998).
Preparation of viruses
Plaque-cloned HIV-1C-2 viruses (IIIB X4 strain) and their
0.5β-escaped HIV-1esc.C-2 viruses (Harada et al., 1985; Masuda
et al., 1990) were obtained from 3-day-old culture supernatants
of persistently infected MOLT-4/HIV-1C-2 and MOLT-4/HIV-
1esc.C-2 cells, respectively. HTLV-I-transformedMT-2 cells were
infected with C-2 viruses and cultured for 4 or 5 days. Progeny
viruses in the supernatant were used as HIV-1C-2(MT-2). After
filtration through a membrane (0.45 μm pore size), the
supernatants were stored at −80 °C until use. X4 envelope-
pseudotyped viruses with a luciferase reporter gene (NL43-luc
viruses) were produced by the calcium phosphate transfection
method (Maeda et al., 2000). 293T cells were cotransfected with
an envelope-deficient NL43 construct carrying the luciferase
gene (pNL43-luc) and a pCXN2 vector expressing the envelope
glycoprotein from pNL43.
Antibodies and reagents
Amouse IgG1 mAb, 0.5β, recognizing 24 amino acids in the
V3 loop of gp120, was used (Matsushita et al., 1988). Three
human anti-HIV mAbs were kindly provided by Dr. Susan
Zolla-Pazner. Specifically, these mAbs were 694/98-D specific
for the V3 region of gp120, 670-30D specific for the C5 region
of gp120 and 246-D specific for the cluster I region of gp41
(Nyambi et al., 2000). An anti-HLA-II antibody (mouse anti-
human HLA DR, DP, DQ) was purchased from Serotec
(Oxford, UK) and stored at a concentration of 20 mg/ml in
phosphate-buffered saline (PBS) at −80 °C. This antibody
recognizes a monomorphic determinant common to each βchain. Sodium azide showed no effects on the HIV-1 infectivity,
adsorption, and membrane fluidity at 0.0002%, which was the
maximum concentration used in this study. Mouse myeloma
ascites IgG1 MOPC21 (Cappel, Cochranville, PA) was used as
an IgG control. Rat LAT12 and LAT27 mAbs, which are non-
neutralizing and neutralizing antibodies against HTLV-I,
respectively, were also used (Tanaka et al., 1991). LAT27
recognizes amino acids 191–196 of HTLV-I gp46. A CXCR4
antagonist, T140, was kindly provided by Drs. H. Tamamura
and N. Fujii (Tamamura et al., 1998). 5-Doxyl stearic acid (5-
DSA) was purchased from Sigma-Aldrich (St. Louis, MO) and
stored at a concentration of 20 mg/ml in ethanol at 4 °C until
use.
Measurement of membrane fluidity in intact cells and viruses
by electron spin resonance (ESR) spectroscopy
For ESR analyses, 1 ml of cells (7×106) or 50 ml of culture
supernatant containing viruses (2–3 μg of p24) were mixed with
1 ml of 60 μg/ml 5-DSA or 25 ml of 90 μg/ml 5-DSA in PBS,
respectively, to make a final concentration of 30 μg/ml, and
incubated at 37 °C for 20 min (Sauerheber et al., 1980). The
cells were washed thrice with PBS to remove the free spin label.
The viruses were centrifuged at 114,000×g for 1 h at 4 °C in a
60 Ti Beckman rotor. The cell or virus pellets were resuspended
in 40 μl of PBS and drawn into capillary tubes. The ends of the
tubes were sealed, before they were placed in quartz glass tubes
and taken from the P3 facility. Spectra were recorded with a
JES-RE1X ESR spectrometer (JEOL, Tokyo, Japan) equipped
with a variable temperature control accessory. The instrument
conditions were 2 min scan time, 5.0 mT sweep width, 0.1 mT
field modulation width, 10 mW microwave power and 0.3 s
time constant (Harada, 2005; Harada et al., 2005, 2007). Fig. 2
shows representative spectra, for which the outer hyperfine
splitting indicates 2A//, and the inner one denotes 2A⊥. The
horizontal axis reflects the varying magnetic fields and the
vertical axis represents the absorption of microwaves. The order
parameter (S) was calculated as follows; S=(A//−A⊥)/[Azz−
(Axx+Ayy)/2]= (A//−A⊥)/27.3G.
Conventional neutralization and MAGI assay
Aliquots (200 μl) of 2-fold-diluted antibodies (anti-HLA-II
or LAT antibodies) were mixed with 200 μl of C-2(MT-2)
viruses, and incubated at 37 °C for 30 min. Next, aliquots
(100 μl/well) of the mixtures were seeded in triplicate on MAGI
cells (8×104/well) that had been split into a flat-bottom 12-well
plate on the previous day. The plate was incubated at 37 °C for
1 h with occasional shaking. After one wash with complete
medium, 1 ml/well of complete medium was added, and the
cells were cultured at 37 °C for 2 days before HIV-1-positive
cells were stained by the MAGI assay. The infected cells were
fixed with 1% formaldehyde and 2% glutaraldehyde in PBS for
5 min, washed twice with PBS, and incubated with staining
solution (3 mM potassium ferrocyanide, 3 mM potassium
ferricyanide, 1 mM MgCl2 and 0.4 mg of X-Gal in PBS) at
37 °C for 40 min (Kimpton and Emerman, 1992). Doses of C-2
149S. Harada et al. / Virology 370 (2008) 142–150(MT-2) and C-2(MOLT-4) viruses were adjusted to make 100 to
200 positive cells per well without antibodies. The percent
neutralization was calculated as follows: (1−positive cells in
test wells/positive cells in control wells)×100.
Blocking of post-attachment enhancement (PAE) and infectivity
assay with luciferase readout
GHOST/CXCR4 cells (2.5×104 cells/well) that had been
seeded into a flat-bottom 48-well plate on the previous day
were infected with 100 μl/well of NL43-luc pseudoviruses
(50 ng p24/ml). Viral adsorption was allowed to take place at
25 °C for 1 h. After one wash with complete medium, the cells
were incubated in the presence or absence of T140 or mAbs
against HIV-1 at 37 °C or 40 °C for 1 h and then washed once
(Harada et al., 2004a, 2005). Subsequently, the plate was
incubated at 37 °C for 2 days, and the infected cells were lysed
with 100 μl/well of luciferase assay buffer (Promega, Madison,
WI). The luciferase activity was measured by adding 50 μl of
luciferase assay substrate (Promega) to 10 μl of cell lysate
and reading the light activity in a luminometer (Lumat LB
9501/16; EG&G Berthold, Bad Wildbad, Germany) (Song
et al., 2001).
Viral adsorption experiment
C-2(MOLT-4) or C-2(MT-2) viruses (400 μl each, 10 ng
p24/ml) were mixed with MOPC21, anti-HLA-II, LAT12,
LAT27 and 0.5β antibodies at final concentrations of 20, 2, 20,
20 and 2 μg/ml, respectively, and incubated at 37 °C for
30 min. MOLT-4 cells (106 cells/tube) were treated with
100 μl/tube of each mixture in triplicate, and incubated at 37 °C
for 1 h. Next, the cells were subjected to two extensive washes
with PBS and lysed with 50 μl/tube of lysis buffer. The amount
of p24 was assessed by ELISA (Cellular Products, Buffalo, NY).
Flow cytometric analysis
MOLT-4 or MT-2 cells (106 cells/tube) were treated with
50 μl of anti-HLA-II (10 μg/ml), LAT12 (10 μg/ml) and LAT27
(10 μg/ml) antibodies at 4 °C for 1 h. After two washes with
PBS, the cells were incubated with 50 μl of fluorescein
isothiocyanate (FITC)-conjugated goat antiserum against
mouse or rabbit antibodies (Organon Teknika, West Chester,
PA) for 1 h at 4 °C. After two washes with PBS, the cells were
resuspended with PBS for analysis using a FACScan system
(Becton Dickinson, Mountain View, CA) (Song et al., 2001).
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